Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOLSTER: LSTA1 + SoC vs SoC in Advanced Solid Tumors
NCT05712356Phase 2Completed
- Sponsor
- Lisata Therapeutics
- Start
- May 2023
- Primary completion
- Apr 2026
- Modality
- Cyclic Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of certepetide in cholangiocarcinoma (CCA), gallbladder cancer, sponsored by Lisata Therapeutics. Started May 2023; status: completed.
02
Drugs
certepetide
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT05712356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05712356.